PHRM.CN PharmaTher (CNQ) C$0.09 on 22 Jan 2026 ahead of earnings: trial catalysts
PHRM.CN stock is trading at C$0.09 on 22 Jan 2026 as investors position ahead of an earnings announcement on 23 Jan 2026. Volume is active at 339,900 shares versus an average of 88,785, signaling market attention. Key drivers for PharmaTher Holdings Ltd. (PHRM.CN) on the CNQ exchange include Phase II/III ketamine trial updates and cash runway metrics. We summarise where valuation, technicals, and company guidance could move the stock during market hours.
Earnings outlook for PHRM.CN stock
PharmaTher reports on 23 Jan 2026, making tomorrow the key event for short-term traders. Management commentary on Phase II/III ketamine programs could change risk assumptions quickly. Investors should watch trial milestones, timeline guidance, and any update to cash burn that affect near-term funding needs. Nasdaq report on PharmaTher notes data delays and liquidity considerations ahead of the release.
Price action and trading metrics for PHRM.CN
The stock opened at C$0.085 and traded between C$0.085 and C$0.095 today, closing at C$0.09 with a 5.88% intraday gain. Volume of 339,900 is 3.83x the average, showing elevated interest. Year high is C$0.77 and year low is C$0.085, highlighting wide volatility on the CNQ market in Canada.
Valuation and financial snapshot
PharmaTher shows negative earnings with EPS -0.02 and a trailing PE of -4.50, reflecting losses. Market capitalization stands at C$8,191,716.00 with 91,019,065 shares outstanding. Cash per share reads C$0.0114 and book value per share is C$0.0086, indicating limited tangible reserves versus market price.
Meyka AI rates PHRM.CN with a score out of 100 and forecast
Meyka AI rates PHRM.CN with a score out of 100: 61.92 | Grade B | Suggestion: HOLD. This grade factors S&P 500 and sector comparisons, financial growth, key metrics, forecasts, and analyst consensus. Meyka AI’s forecast model projects a 12‑month value of C$0.278 compared with the current C$0.09, implying 208.94% upside. Forecasts are model-based projections and not guarantees.
Risks, catalysts, and sector context
Key risks include clinical trial failure, dilution, and thin liquidity for small‑cap biotech on the CNQ. A positive Phase II/III update would be the primary catalyst and could re-rate the stock relative to healthcare peers. The healthcare sector in Canada shows mixed performance, and biotech volatility usually exceeds sector averages, increasing both upside and downside potential.
Technical snapshot and momentum
Momentum indicators show oversold conditions with RSI 37.10 and CCI -212.12, while MACD sits near neutral. Bollinger Bands range from C$0.09 to C$0.12, and ADX 9.42 suggests no clear trend. Elevated relative volume and low price create sharp intraday moves; traders should use limit orders and check liquidity on CNQ.
Final Thoughts
PHRM.CN stock trades at C$0.09 on 22 Jan 2026 with heightened volume ahead of a 23 Jan 2026 earnings update focused on ketamine program progress. The balance sheet shows small cash per share and negative EPS -0.02, underlining financing and execution risk. Meyka AI’s forecast model projects a 12‑month value near C$0.278, implying roughly 208.94% upside versus the current price, but this is a model projection and not a guarantee. For traders, the immediate play is binary: clinical or guidance news can swing the share price sharply. For longer‑term investors, valuation and funding pathways must improve before considering a buy. We use this earnings spotlight to stress test scenarios and urge checking trial readouts and liquidity before acting. For further company filings and market context, see PharmaTher’s site and recent market notes on Nasdaq and Seeking Alpha. Meyka AI provides this analysis as an AI‑powered market analysis platform, not financial advice.
FAQs
When does PharmaTher report earnings and what to expect?
PharmaTher’s earnings announcement is scheduled for 23 Jan 2026. Expect updates on Phase II/III ketamine trials, cash runway commentary, and any guidance that could change near‑term funding needs.
What are the main valuation metrics for PHRM.CN stock?
Key metrics: price C$0.09, EPS -0.02, PE -4.50, market cap C$8,191,716.00, book value per share C$0.0086. These show a small market cap and negative profitability.
How reliable is Meyka AI’s forecast for PHRM.CN?
Meyka AI’s forecast model projects C$0.278 in 12 months, implying 208.94% upside versus C$0.09. Forecasts are model‑based projections and not guarantees; they should complement independent research.
Is PHRM.CN stock liquid enough for active trading?
Liquidity is limited. Today’s volume of 339,900 exceeded the average 88,785, but the low absolute price and wide spreads increase execution risk. Use limit orders and monitor bid‑ask spreads on CNQ.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.
